Tesamorelin Research for Cognitive Function
An evidence-based overview of research examining Tesamorelin in the context of cognitive function. This page synthesizes findings from peer-reviewed literature.
Research Summary
A 73-participant open-label phase 2 trial in virally suppressed adults with HIV, abdominal obesity, and neurocognitive impairment compared tesamorelin with standard care for six months. The between-group cognitive difference was not significant (P=.673), despite a smaller waist circumference. An older 152-person placebo-controlled trial of GHRH/tesamorelin in older adults with normal cognition or mild cognitive impairment reported a favorable cognitive signal, but it used a different population. A 2026 placebo-controlled pilot of 22 adults found no significant direct changes in its study measures after 10 weeks. Neither trial establishes an approved cognitive indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.